Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 3, 1999, Pages 389-392

  Wu, Ya Li ^a   Scott, Eileen M ^a   Li Wan Po, Alain ^b   Tariq, Vicki N ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZLOCILLIN; BETA LACTAMASE; TOBRAMYCIN; TOBRAMYCIN SULFATE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; CYSTIC FIBROSIS; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; TITRIMETRY;

ANTI-BACTERIAL AGENTS; AZLOCILLIN; CYSTIC FIBROSIS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TOBRAMYCIN;

EID: 0032860408     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.3.389     Document Type: Article

References (9)

1. McLaughlin, F. J., Matthews, W. J., Strieder, D. J., Sullivan, B., Taneja, A., Murphy, P. et al. (1983). Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. Journal of Infectious Diseases 147, 559-67.
2. Farrell, W., Wilks, M. & Drasar, F. A. (1979). Synergy between aminoglycosides and semi-synthetic penicillins against gentamicin-resistant Gram-negative rods. Journal of Antimicrobial Chemotherapy 5, 23-9.
3. Moellering, R. C., Allsop, A., Bush, K., Quinn, J., Baquero, F. & Philipps, I. (1998). Antibiotic resistance: lessons for the future. Clinical Infectious Diseases 27, Suppl. 1, S135-40.
4. Wu, Y. L., Scott, E. M., Li Wan Po, A. & Tariq, V. N. (1999). Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations. APMIS 107, in press.
5. Steen, H. J., Scott., E. M., Stevenson, M. I., Black, A. E., Redmond, A. O. B. & Collier, P. S. (1989). Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of Pseudomonas infection in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 24, 787-95.
6. Giwercman, B., Lambert, P. A., Rosdahl, V. T., Shand, G. H. & Høiby, N. (1990). Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains. Journal of Antimicrobial Chemotherapy 26, 247-59.
7. Hancock, R. E. W. (1998). Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative Gram-negative bacteria. Clinical Infectious Diseases 27, Suppl. 1, S93-9.
8. Eliopoulos, G. M. (1988). Induction of β-lactamases. Journal of Antimicrobial Chemotherapy 22, Suppl. A, 37-44.
9. Barriere, S. L. (1992). Bacterial resistance to β-lactams, and its prevention with combination antimicrobial therapy. Pharmacotherapy 12, 397-402.